---
document_datetime: 2024-09-10 14:07:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_en.pdf
document_name: abrysvo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.6267352
conversion_datetime: 2025-12-22 00:04:56.316059
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                           | Route of administration   | Immediate Packaging                                       | Content (concentration)   | Pack size                                                 |
|------------------|-------------------|------------|-----------------------------------------------|---------------------------|-----------------------------------------------------------|---------------------------|-----------------------------------------------------------|
| EU/1/23/1752/001 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 1 vial + 1 vial adaptor + 1 pre-filled syringe + 1 needle |
| EU/1/23/1752/002 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 1 vial + 1 vial adaptor + 1 pre-filled syringe            |
| EU/1/23/1752/003 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 5 vials + 5 vial adaptors + 5 pre-filled syringes + 5     |
| EU/1/23/1752/004 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 5 vials + 5 vial adaptors + 5 pre-filled syringes         |
| EU/1/23/1752/005 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 10 vials + 10 vial adaptors + 10 pre-filled syringes + 10 |
| EU/1/23/1752/006 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml                    | 10 vials + 10 vial adaptors + 10 pre-filled syringes      |
| EU/1/23/1752/007 | Abrysvo           | --¹        | Powder and solvent for solution for           | Intramuscular use         | powder: vial (glass); solvent: vial (glass)               | 0.5 ml                    | 5 vials + 5 vials                                         |
| EU/1/23/1752/008 | Abrysvo           | --¹        | Powder and solvent for solution for injection | Intramuscular use         | powder: vial (glass); solvent: vial (glass)               | 0.5 ml                    | 10 vials + 10 vials                                       |

--¹

After reconstitution, one dose (0.5 mL) contains: RSV subgroup A stabilised prefusion F antigen *,** 60 micrograms

<div style=\"page-break-after: always\"></div>

| MA (EU) number                                                                                                                                                                                      | (Invented) name Strength                                                                                                                                                                            | Pharmaceutical form                                                                                                                                                                                 | Route of administration                                                                                                                                                                             | Immediate Packaging                                                                                                                                                                                 | Content (concentration)                                                                                                                                                                             | Pack size                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology | RSV subgroup B stabilised prefusion F antigen *,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology |